Loading…
Unresolved issues associated with early initiation of antiplatelet therapy in acute coronary syndromes
Early initiation of antiplatelet therapy in addition to aspirin is critical for all patients with acute coronary syndrome (ACS) due to improved short- and long-term outcomes. Thus, evidence-based practice guidelines for ACS management recommend early and intensive initiation of antiplatelet therapy...
Saved in:
Published in: | The Journal of invasive cardiology 2010-01, Vol.22 (1), p.40-44 |
---|---|
Main Author: | |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 44 |
container_issue | 1 |
container_start_page | 40 |
container_title | The Journal of invasive cardiology |
container_volume | 22 |
creator | Alagona, Jr, Peter |
description | Early initiation of antiplatelet therapy in addition to aspirin is critical for all patients with acute coronary syndrome (ACS) due to improved short- and long-term outcomes. Thus, evidence-based practice guidelines for ACS management recommend early and intensive initiation of antiplatelet therapy with aspirin, clopidogrel, and/or glycoprotein (GP) IIb/IIIa inhibitors. Despite the comprehensive nature of current guidelines, several important clinical issues concerning the optimal initiation of antiplatelet therapy remain. This review addresses four of these clinical issues: When should GP IIb/IIIa inhibitors be initiated? When should clopidogrel be initiated? What is the optimal clopidogrel loading dose? How should antiplatelet therapy be approached in chronically anticoagulated patients? |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_733928341</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733928341</sourcerecordid><originalsourceid>FETCH-LOGICAL-p210t-4ee3a8b5a30c808939166e4bd10f1732bb0b865f0684fa8a92dd1481027e460e3</originalsourceid><addsrcrecordid>eNo1kE1LxDAYhIMg7rr6FyQ3T4U3H23Toyx-wYIX91zS9i0bSZOapEr_vRHX08DwMMzMBdmysqwLXgLbkOsYPwA4Ew27IhsOIJVomi0Zjy5g9PYLB2piXDBSHaPvjU7Z-TbpRFEHu1LjTMqm8Y76kWqXzGwzYzHRdMKg51-E6n5JSHsfvNNhpXF1Q_ATxhtyOWob8fasO3J8enzfvxSHt-fX_cOhmDmDVEhEoVVXagG9AtXktlWFshsYjKwWvOugU1U5QqXkqJVu-DAwqRjwGmUFKHbk_i93Dv4zj0ntZGKP1mqHfoltLUTDlZAsk3dncukmHNo5mClXbv-vET91iWC2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733928341</pqid></control><display><type>article</type><title>Unresolved issues associated with early initiation of antiplatelet therapy in acute coronary syndromes</title><source>Freely Accessible Journals</source><creator>Alagona, Jr, Peter</creator><creatorcontrib>Alagona, Jr, Peter</creatorcontrib><description>Early initiation of antiplatelet therapy in addition to aspirin is critical for all patients with acute coronary syndrome (ACS) due to improved short- and long-term outcomes. Thus, evidence-based practice guidelines for ACS management recommend early and intensive initiation of antiplatelet therapy with aspirin, clopidogrel, and/or glycoprotein (GP) IIb/IIIa inhibitors. Despite the comprehensive nature of current guidelines, several important clinical issues concerning the optimal initiation of antiplatelet therapy remain. This review addresses four of these clinical issues: When should GP IIb/IIIa inhibitors be initiated? When should clopidogrel be initiated? What is the optimal clopidogrel loading dose? How should antiplatelet therapy be approached in chronically anticoagulated patients?</description><identifier>EISSN: 1557-2501</identifier><identifier>PMID: 20048399</identifier><language>eng</language><publisher>United States</publisher><subject>Acute Coronary Syndrome - drug therapy ; Aspirin - therapeutic use ; Dose-Response Relationship, Drug ; Humans ; Platelet Aggregation Inhibitors - therapeutic use ; Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors ; Ticlopidine - analogs & derivatives ; Ticlopidine - therapeutic use ; Time Factors</subject><ispartof>The Journal of invasive cardiology, 2010-01, Vol.22 (1), p.40-44</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20048399$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alagona, Jr, Peter</creatorcontrib><title>Unresolved issues associated with early initiation of antiplatelet therapy in acute coronary syndromes</title><title>The Journal of invasive cardiology</title><addtitle>J Invasive Cardiol</addtitle><description>Early initiation of antiplatelet therapy in addition to aspirin is critical for all patients with acute coronary syndrome (ACS) due to improved short- and long-term outcomes. Thus, evidence-based practice guidelines for ACS management recommend early and intensive initiation of antiplatelet therapy with aspirin, clopidogrel, and/or glycoprotein (GP) IIb/IIIa inhibitors. Despite the comprehensive nature of current guidelines, several important clinical issues concerning the optimal initiation of antiplatelet therapy remain. This review addresses four of these clinical issues: When should GP IIb/IIIa inhibitors be initiated? When should clopidogrel be initiated? What is the optimal clopidogrel loading dose? How should antiplatelet therapy be approached in chronically anticoagulated patients?</description><subject>Acute Coronary Syndrome - drug therapy</subject><subject>Aspirin - therapeutic use</subject><subject>Dose-Response Relationship, Drug</subject><subject>Humans</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors</subject><subject>Ticlopidine - analogs & derivatives</subject><subject>Ticlopidine - therapeutic use</subject><subject>Time Factors</subject><issn>1557-2501</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNo1kE1LxDAYhIMg7rr6FyQ3T4U3H23Toyx-wYIX91zS9i0bSZOapEr_vRHX08DwMMzMBdmysqwLXgLbkOsYPwA4Ew27IhsOIJVomi0Zjy5g9PYLB2piXDBSHaPvjU7Z-TbpRFEHu1LjTMqm8Y76kWqXzGwzYzHRdMKg51-E6n5JSHsfvNNhpXF1Q_ATxhtyOWob8fasO3J8enzfvxSHt-fX_cOhmDmDVEhEoVVXagG9AtXktlWFshsYjKwWvOugU1U5QqXkqJVu-DAwqRjwGmUFKHbk_i93Dv4zj0ntZGKP1mqHfoltLUTDlZAsk3dncukmHNo5mClXbv-vET91iWC2</recordid><startdate>201001</startdate><enddate>201001</enddate><creator>Alagona, Jr, Peter</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201001</creationdate><title>Unresolved issues associated with early initiation of antiplatelet therapy in acute coronary syndromes</title><author>Alagona, Jr, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p210t-4ee3a8b5a30c808939166e4bd10f1732bb0b865f0684fa8a92dd1481027e460e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Acute Coronary Syndrome - drug therapy</topic><topic>Aspirin - therapeutic use</topic><topic>Dose-Response Relationship, Drug</topic><topic>Humans</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors</topic><topic>Ticlopidine - analogs & derivatives</topic><topic>Ticlopidine - therapeutic use</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alagona, Jr, Peter</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of invasive cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alagona, Jr, Peter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Unresolved issues associated with early initiation of antiplatelet therapy in acute coronary syndromes</atitle><jtitle>The Journal of invasive cardiology</jtitle><addtitle>J Invasive Cardiol</addtitle><date>2010-01</date><risdate>2010</risdate><volume>22</volume><issue>1</issue><spage>40</spage><epage>44</epage><pages>40-44</pages><eissn>1557-2501</eissn><abstract>Early initiation of antiplatelet therapy in addition to aspirin is critical for all patients with acute coronary syndrome (ACS) due to improved short- and long-term outcomes. Thus, evidence-based practice guidelines for ACS management recommend early and intensive initiation of antiplatelet therapy with aspirin, clopidogrel, and/or glycoprotein (GP) IIb/IIIa inhibitors. Despite the comprehensive nature of current guidelines, several important clinical issues concerning the optimal initiation of antiplatelet therapy remain. This review addresses four of these clinical issues: When should GP IIb/IIIa inhibitors be initiated? When should clopidogrel be initiated? What is the optimal clopidogrel loading dose? How should antiplatelet therapy be approached in chronically anticoagulated patients?</abstract><cop>United States</cop><pmid>20048399</pmid><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | EISSN: 1557-2501 |
ispartof | The Journal of invasive cardiology, 2010-01, Vol.22 (1), p.40-44 |
issn | 1557-2501 |
language | eng |
recordid | cdi_proquest_miscellaneous_733928341 |
source | Freely Accessible Journals |
subjects | Acute Coronary Syndrome - drug therapy Aspirin - therapeutic use Dose-Response Relationship, Drug Humans Platelet Aggregation Inhibitors - therapeutic use Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors Ticlopidine - analogs & derivatives Ticlopidine - therapeutic use Time Factors |
title | Unresolved issues associated with early initiation of antiplatelet therapy in acute coronary syndromes |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T00%3A33%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Unresolved%20issues%20associated%20with%20early%20initiation%20of%20antiplatelet%20therapy%20in%20acute%20coronary%20syndromes&rft.jtitle=The%20Journal%20of%20invasive%20cardiology&rft.au=Alagona,%20Jr,%20Peter&rft.date=2010-01&rft.volume=22&rft.issue=1&rft.spage=40&rft.epage=44&rft.pages=40-44&rft.eissn=1557-2501&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E733928341%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p210t-4ee3a8b5a30c808939166e4bd10f1732bb0b865f0684fa8a92dd1481027e460e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=733928341&rft_id=info:pmid/20048399&rfr_iscdi=true |